Orgenesis shares are trading higher after the company announced it entered into an agreement with CGT Global to expand patient access and cell and gene therapy development across the United States.
Portfolio Pulse from Benzinga Newsdesk
Orgenesis has entered into an agreement with CGT Global to expand patient access and cell and gene therapy development across the United States. This has led to an increase in the company's share prices.
September 21, 2023 | 2:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Orgenesis' agreement with CGT Global to expand patient access and cell and gene therapy development in the US has led to a rise in its share prices.
The agreement with CGT Global is a positive development for Orgenesis as it expands its reach in the US market. This has led to increased investor confidence, reflected in the rise in share prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100